Skip to main content
. 2022 Oct 27;29(7):1200–1208. doi: 10.1158/1078-0432.CCR-22-2145

Figure 1.

Figure 1. CONSORT diagram of the two-arm randomized trial. Patients were randomly assigned to either the cediranib arm or the sunitinib arm. Crossover was allowed at disease progression.

CONSORT diagram of the two-arm randomized trial. Patients were randomly assigned to either the cediranib arm or the sunitinib arm. Crossover was allowed at disease progression.